Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Blood

Volumn 115, Issue 3, 2010, Pages 475-480

  Di Bella, Nicholas ^a,b   Taetle, Raymond ^a,c   Kolibaba, Kathryn ^a,d   Boyd, Thomas ^a,e   Raju, Robert ^a,f   Barrera, David ^a,g   Cochran Jr , Ernest W ^a,g   Dien, Philip Y ^a,h   Lyons, Roger ^a,i   Schlegel, Peter J ^a,j   Vukelja, Svetislava J ^a,g   Boston, Julie ^a   Boehm, Kristi A ^a   Wang, Yunfei ^a   Asmar, Lina ^a  

^a US Oncology Research Inc   (United States)

^b ROCKY MOUNTAIN CANCER CENTERS   (United States)

^c Hematology and Oncology Physicians   (United States)

^d Northwest Cancer Specialists   (United States)

^e Yakima Valley Memorial Hospital   (United States)

^f Dayton Oncology and Hematology   (United States)

^g TEXAS ONCOLOGY   (United States)

^h Minnesota Hematology Oncology   (United States)

ⁱ Cancer Care Centers of South Texas   (United States)

^j Cancer Care Northwest   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; BORTEZOMIB; FAMCICLOVIR; RITUXIMAB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FEVER; HERPES ZOSTER; HUMAN; HYPOKALEMIA; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RESPIRATORY TRACT INFECTION; SEPSIS; SINUSITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS INFECTION; WEAKNESS; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77449160650     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-233155     Document Type: Article

References (27)

1. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59(11):2615-2622.
2. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5(9): 2638-2645.
3. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001; 61(19):3535-3540.
4. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996-5000.
5. Pink MM, Pien CS, Ona VO, Worland P, Adams J, Kauffman MG. PS-341 enhances chemotherapeutic effect in human xenograft models. Proc Am Assoc Cancer Res. 2002;abstract 787.
6. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001;82(1):110-122.
7. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001;100(1): 11-17.
8. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50(1):183-193.
9. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7(5):1419-1428.
10. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62(4):1083-1086.
11. McConkey DJ, Pettaway C, Elliott P, et al. The proteasome as a new drug target in metastatic prostate cancer. 7th Annual Genitourinary Oncology Conference. Houston, TX, 1999; Abstract.
12. Millennium Pharmaceuticals, Inc. VELCADE (bortezomib) package insert. Cambridge, MA. June 2008.
13. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076.
14. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420-4427.
15. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23(4):676-684.
16. O'Connor OA. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). J Clin Oncol. 2002;22:abstract 6582.
17. Blum KA, Baiocchi RA, Alinari L, et al. A phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 3053.
18. Moosmann PR, Heizmann M, Kotrubczik N, Bargetzi M, Wernli M. Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkin's lymphoma: a single-center phase 1/2 study. Blood (ASH Annual Meeting Abstracts). 2008; 112(11):Abstract 1574.
19. David KA, Smith MR, Lossos IS, et al. A phase II trial of combination bortezomib (Velcade®) and rituximab for untreated "high tumor burden" indolent non-Hodgkin lymphoma (NHL). Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 2004.
20. Grant S, Sullivan D, Roodman D, et al. Phase I trial of bortezomib (NSC 681239) and flavopiridol (NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 1573.
21. Cheson BD. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4): 1244-1253.
22. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
23. Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown; 1994:253-256.
24. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc-v30.html. Accessed May 26, 2009.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
26. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer. 2006;119(5):971-979.
27. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(4):667-675.